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Abstract  
Stable renal transplant recipients (RTR) display high rates of atherosclerotic events (AE). 
Innate immunity and especially vascular inflammation play a role in the pathogenesis of 
atherosclerosis. It is illustrated both by an increased occurrence of post-renal transplant 
cardiovascular events in patients with elevated levels of C-reactive protein and by a correlation 
between post-transplant AE and Toll-like receptor-4 Asp299Gly polymorphism. Here, we 
analyze the influence NOD2/CARD15 gene polymorphism since NOD2 can modulate 
macrophage pro-inflammatory activity and macrophage is present in early atherosclerotic 
lesions. The incidence of single nucleotide polymorphism (SNP) in the three major 
polymorphic region of NOD2 gene (SNP8, SNP12 and SNP13) was assessed in 182 RTR and 
the correlation between such polymorphism and the development of AE was analyzed. No 
correlation was observed between NOD2 gene polymorphism and the occurrence of AE after 
renal transplantation. NOD2 gene polymorphism thus does not appear to influence 
cardiovascular complications in RTR. 
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Stable renal transplant recipients (RTRs) display disproportionately high rates of 
atherosclerotic events (AE) (1). It is now established that both vascular inflammation and 
components of the immune system are involved in the pathogenesis of atherosclerosis (2). We 
have already shown the importance of inflammatory and innate immunity in the pathogenesis 
of atherosclerosis after renal transplantation by demonstrating a correlation between the 
occurrence of post-transplant cardiovascular events and i) elevated circulating levels of C-
reactive protein (3) and ii) Toll-like receptor-4 (TLR4) Asp299Gly polymorphism (4). Here, 
we analyze NOD2/CARD15 (Nucleotide Oligomerisation Domain-2/Caspase-Recruitment 
Domain-15, thereafter called NOD2) gene polymorphism. Three major single nucleotide 
polymorphisms (SNP) have been reported in NOD2 gene; SNP8, 12 and 13 alleles have been 
previously associated with increased susceptibility for two inflammatory diseases: Crohn’s 
disease (5,6) and Graft-versus-Host Disease (GVHD) after allogeneic hematopoietic cell 
transplantation (7). This suggests that NOD2 gene polymorphism modulates pro-inflammatory 
diseases. NOD2 is expressed in macrophages (8,9) and macrophages are present in 
atherosclerotic lesions at early stages (10). To date, no study has evaluated the impact of 
NOD2 gene polymorphism on AE after transplantation. We assessed the frequency of NOD2 
gene polymorphism in 182 RTRs and analyzed the relationship between such polymorphism 
and the development of atherosclerotic complications. 
One hundred and eighty-two RTRs were enrolled in this trial. These patients have been 
transplanted between January 1990 and December 2000. Age, gender, body mass index 
(weight [Kg]/size
2
 [m
2
]), past history of cardiovascular disease (CVD) and other risk factors 
were collected at transplant time (TABLE 1). Mean age was 46 + 13 years, and 117 RTRs 
(64.3 %) were men (TABLE 1). Mean follow- up of these 182 patients was 7.5 + 2.3 years 
post-transplant. These 182 RTRs were genotyped for SNP8, SNP12 and SNP13 of NOD2 
gene. Genomic DNA was extracted from white blood cells using standard salting out 
procedure. Analysis of each NOD2 variants was then performed using a polymerase chain 
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reaction (PCR)-based genotyping assay with specific primers, as described (5). After PCR 
amplification of the polymorphic regions of interest, PCR products were digested overnight 
with Msp I, Hha I and ApaI restriction endonuclease (New England Biolabs, Beverly, USA), 
for SNP8, SNP12 and SNP13 respectively (5), as recommended by the supplier. Digestion 
products were then separated by a 2% standard agarose gel electrophoresis (Fig. 1). For each 
PCR, a negative control (PCR amplification without genomic DNA) was included. We added 
systematically a mutated DNA to control digestion procedures. Researchers and laboratory 
staff did not have any access to identifiable information and could identify samples by number 
only. 
Post-transplant AE, i.e., coronary heart disease, stroke/cerebrovascular disease and abdominal 
aortic or lower extremity arterial disease, were diagnosed according to published criteria (11). 
Thirty-eight (20.7%) patients presented AE: 19 coronary heart diseases, 8 cerebrovascular 
diseases and 11 lower extremity arterial diseases. Statistical analysis was performed using 
Statview 5 (SAS institute Inc., Cary, NC). Arithmetic mean was calculated and expressed as 
+ standard deviation (SD). Dichotomic variables were compared with the  test and 
continuous variables with the Student t test. Using log-rank tests on Kaplan Meier 
nonparametric estimates of the survival without AE distribution, we selected variables with a 
p value lower than, or equal to, 0.20. The selected variables were included into a Cox 
proportional hazard model, and a backward stepwise selection process was performed, this 
time at a classical α = 0.05. 
The incidence of heterozygous genotype carriers observed in the RTR cohort was limited: 
8.8% (n=16), 4.4% (n=8) and 1.6% (n=3) for SNP8, SNP12 and SNP13, respectively. NOD2 
allele and genotype frequencies are summarized in TABLE 2. As previously described (5,6), 
we did not find either heterozygous composites or homozygous mutants (TABLE 2). We 
observed more SNP12 heterozygote patients (4.4%; TABLE 2) than in a previous publication 
reporting SNP12 incidence (0.72 and 1.23%) in two independent Caucasian populations (6). 
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We did not find any relationship between NOD2 gene polymorphism and major complications 
observed after renal transplantation, including: acute rejection, CMV disease, bacterial or 
opportunistic infections, and death (TABLE 1). When focusing on occurrence of AE after renal 
transplantation, no correlation was also found (hazard ratio, HR, 1.12; 95% confidence 
interval, CI, 0.69 to 2.01; p=0.31) (TABLE 1&2). In multivariate analysis, older age (HR, 4.77; 
95% CI, 2.37 to 9.80), a past history of cardiovascular disease (relative risk, RR, 3.20; 95% CI, 
1.49 to 6.45), male gender (HR, 1.99; 95%CI, 0.99 to 3.78); and diabetes mellitus (RR, 1.48; 
95% CI, 1.11 to 2.75) predicted independently the risk of AE. This contrasts with the 
implication of NOD2 gene polymorphisms in other inflammatory diseases such as Crohn’s 
disease (5,6) and GVHD (7). Several limitations should however be considered. The 
population studied was limited with regards to the frequency of polymorphism. However, the 
total number of patients was not very different from a previous publication associating NOD2 
gene polymorphism and Crohn’s disease occurrence (6). Furthermore, study design leads to 
include patients with a low CVD risk. However, with nearly the same cohort, we had 
previously shown that RTRs with TLR4 Asp299Gly polymorphism exhibited a lower risk of 
post-transplant AE (4). This led us to discuss the respective roles of NOD2 and TLR4 in 
pathogen recognition. NOD2, like TLRs, belongs to a large family of proteins involved in 
infectious pathogen recognition (12). As known for TLR4 at the cell membrane, intracellular 
NOD2 protein has been proposed to play a role in the intracytoplasmic response to bacterial 
cell wall products (muramyl dipeptide) and subsequent NF-B activation in macrophages (12). 
In our previous study (4), RTRs with Asp299Gly TLR-4 polymorphism were less likely to 
experience post-transplant AE (RR=0.44), but developed more frequently severe bacterial 
infections (RR=1.33) and opportunistic infections (RR=3.03). These previous data together 
with the present data (i.e., absence of correlation between a particular NOD2 gene 
polymorphism and post-transplant AE occurrence) could support the idea that bacterial 
infections do not play a major role in the development of atherosclerosis. The relationship 
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between infectious pathogens and atherosclerosis, originally suggested by seroepidemiologic 
studies (13), was also confirmed by a series of investigations demonstrating the presence of 
pathogens in atherosclerotic lesions (14). On the other hand, transient prophylactic antibiotic 
treatment did not prevent secondary coronary syndromes (15,16). Therefore, the etiologic or 
pathogenic significance of bacterial infections in CVD remains to be determined. Finally, the 
functional role of NOD2 is still unclear. Most studies which implicated NOD2 in pro-
inflammatory NF-B pathway in macrophages were performed in vitro (8,9). They suggested 
that the association of NOD2 mutations was characterized by a diminished NF-B response 
(8,9). However, the first functional study performed in vivo, using C57BL/6 mice deficient for 
NOD2 gene (NOD2-/- mice), did not confirm such in vitro results (17). Macrophages from 
NOD2-/- mice responded normally to TLR ligands in terms of NF-B activation and 
inflammatory cytokine production (17). These results suggest the absence of NOD2 
implication in NF-B activation in macrophage. A more recent study using NOD2-/- mice 
reported that NOD2 was especially critical to regulate innate bacterial immunity in the 
intestinal tract (18). This was attested by an increased susceptibility of NOD2-/- mice to 
intragastric infection with Listeria monocytogenes but not after intravenous or intraperitoneal 
injection of these bacteria (18). NOD2 is highly expressed in crypts from the terminal ileum 
(18) in Paneth cells (19). This may explain why NOD2 mutations render patients susceptible to 
Crohn’s diseases, a chronic inflammatory bowel disease (5,6) and GVHD (7). It is believed 
that the loss of gastrointestinal tract integrity, and the translocation of endogenous endotoxins 
into the systemic circulation, is a critical event in the initiation of GVHD (20). Overall, NOD2 
mutations may not have a major influence of vascular inflammation and this may account for 
the results we are reporting here. Lastly, one has to consider the potential influence of NOD2 
and TLR4 ligands. TLR4 ligands are generally stronger NF-B activators than NOD2 ligands 
(12). In addition to pathogens, a number of endogenous ligands (e.g., heat shock proteins 
known to be present in atherosclerotic lesions, extracellular matrix proteins,…) have been 
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shown to stimulate TLR4 (12). This again may explain why we found a relationship with 
TLR4 Asp299Gly polymorphism while not with NOD2 gene polymorphism. 
In conclusion, NOD2 gene polymorphism is not associated with AE in RTRs population and 
should not be proposed to assess CVD risk in RTRs. These results underline recent data 
showing that bacterial infections are not involved in CVD (15,16) and the major role of NOD2 
is to control intestinal inflammation (18). 
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TABLE 1. Comparison of baseline characteristics and main outcome after 
transplantation in 182 renal transplant recipients (RTR) presenting a wild type genotype 
of the NOD2 gene versus RTRs presenting a mutation in SNP8, SNP12 or SNP13 of the 
NOD2 gene. 
 
 
Wild type genotype 
carriers 
n = 155 (85.2%) 
NOD2 
polymorphism 
carriers
a
 
n = 27 (14.8%) 
Age (years) 45.8 + 13.8
a
 49.4 + 9.2
a
 
Sex ratio (Male / Female) 
97 / 58 
(62.6% / 37.4%) 
20 / 7 
(74% / 26%) 
Pre-transplant Body Mass Index (kg/m
2
) 22.6 + 4.1
b
 24.3 + 4.2
b
 
Past history of cardiovascular disease 8 (5.1%) 0 
Hypertension 85 (54.8%) 17 (62.9%) 
Dyslipidaemia 61 (39.3%) 10 (37%) 
Diabetes mellitus (DM) / post-transplant 
DM 
8 (5.2%) / 18 
(11.6%) 
1 (3.7%) / 5 (18.5%) 
Homocysteine (µmol/l) 16.6 + 5.5
a
 15.2 + 6.7
a
 
Cigarette smoking 15 (9.7%) 5 (18.5%) 
Atherosclerotic events after 
transplantation 
32 (20.6%) 6 (22.2%)
c
 
Opportunistic infections 39 (25.2%) 5 (18.5%) 
CMV disease 38 (24.5%) 5 (18.5%) 
Bacterial infections 55 (35.5%) 7 (25.9%) 
Acute rejection 30 (19.3%) 6 (22.2%) 
Death after transplantation 5 (3.2%) 2 (7.4%) 
Results are expressed in Kg/m
2
 for body mass index, in µmol/l for homocysteine, in years for 
age and for other items as number of patients and percentage in brackets. 
a
 heterozygote RTRs with a mutated NOD2 allele in either SNP8, SNP12 or SNP13 region 
(since no heterozygous composites or homozygous mutants were detected); 
b
 mean + SD; 
c
 2 
patients with a mutated SNP8, 2 with a mutated SNP12 and 2 with a mutated SNP13 developed 
AE (see also TABLE 2). 
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TABLE 2. Comparison of NOD2 gene polymorphism incidence in renal transplant 
recipients (RTR) enrolled in our cohort with three previously published cohorts including 
patients suffering from Crohn’s Disease 
 
  polymorphism 
incidence 
in RTR 
(n=182) 
AE in 
these 
RTR 
(n=38) 
polymorphism 
incidence 
in Ref. 5 
(n=300) 
polymorphism 
incidence 
in Ref. 6 
(n=373) 
polymorphism 
incidence 
in Ref. 6 
(n=202) 
 
SNP8 
WT 166 (91.2%) 36 
(21.7%) 
289 (96.3%) 95.2% 97.2% 
H/h 16 (8.8%) 2 
(12.5%) 
11 (3.7%) 4.8% 2.8% 
DM 0 0 0 0 0 
 
SNP12 
WT 174 (95.6%) 36 
(20.7%) 
300 (100%) 99.3% 98.8% 
H/h 8 (4.4%) 2 (25%) 0 0.7% 1.2% 
DM 0 0 0 0 0 
 
SNP13 
WT 179 (98.4%) 36 
(20.1%) 
290 (96.7%) 95.9% 98.8% 
H/h 3 (1.6%) 2 
(66.6%) 
10 (3.3%) 4.1% 1.2% 
DM 0 0 0 0 0 
Results are expressed as number of patients and/or percentage.  
Abbreviations used: WT: RTRs with a wild type NOD2 gene; H/h: heterozygote RTRs with a 
mutated NOD2 allele in either SNP8, SNP12 or SNP13 region (since no heterozygous 
composites or homozygous mutants were detected); DM: double mutated patients or 
homozygous mutants; AE: atherosclerotic events. 
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FIGURE LEGEND 
Figure 1. A representative analysis of NOD2 gene polymorphism by restriction fragment 
length polymorphism (RFLP)-PCR. Agarose gel electrophoresis of RFLP-PCR after MspI, 
HhaI, or ApaI overnight restriction digest, respectively, for SNP8 (left panel) SNP12 (middle 
panel) and SNP13 (right panel) polymorphisms. WT corresponds to DNA from a wild type 
patient, while h corresponds to DNA from a heterozygote patient. PCR corresponds to 
undigested PCR products of 185 bp, 163 bp, and 151 bp, respectively, for SNP8, SNP12 and 
SNP13 polymorphisms. MW represents molecular weight marker where the 3 bands are 
100bp, 200 bp and 300 bp in length. In h samples,  symbol depicts the mutated allele, 
whereas  depicts the wild type allele.  
 
 
